Protara Therapeutics (TARA) Operating Expenses (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Operating Expenses data on file, last reported at $19.6 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 38.98% year-over-year to $19.6 million in Q1 2026; TTM through Mar 2026 was $70.1 million, a 36.22% increase from a year earlier, with the FY2025 full-year figure at $64.5 million, up 31.32% from the prior year.
• Operating Expenses for Q1 2026 stood at $19.6 million, up from $19.1 million in the prior quarter.
• Over the last five years, Operating Expenses for TARA reached as high as $39.5 million in Q4 2022 and fell as low as $8.0 million in Q3 2022.
• Historically, Operating Expenses has averaged $14.4 million across 5 years, with a median of $12.1 million in 2023.
• Across the five-year window, Operating Expenses surged 284.07% in 2022 and tumbled 72.05% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $39.5 million in 2022, then tumbled by 72.05% to $11.0 million in 2023, then increased by 29.63% to $14.3 million in 2024, then surged by 33.31% to $19.1 million in 2025, then gained by 2.88% to $19.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $19.6 million in Q1 2026, $19.1 million in Q4 2025, and $14.8 million in Q3 2025.